Abstract
Zika virus (ZIKV) has caused great public concerns due to its recent large outbreaks and a close association with microcephaly in fetus and Guillain-Barre syndrome in adults. Rapid development of vaccines against ZIKV is a public health priority. To this end, we have constructed and purified recombinant ZIKV envelope protein using both prokaryotic and eukaryotic expression systems, and then tested their immunogenicity and protective efficacy in immune competent mice. Both protein immunogens elicited humoral and cellular immune responses, and protected immune competent mice from ZIKV challenge in vivo. These products could be further evaluated either as stand-alone vaccine candidate, or used in a prime-and-boost regimen with other forms of ZIKV vaccine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Neutralizing / blood*
-
Antibodies, Viral / blood
-
Antibodies, Viral / immunology
-
Female
-
Immunity, Cellular / immunology*
-
Mice
-
Mice, Inbred BALB C
-
Recombinant Proteins / immunology*
-
Vaccination
-
Viral Envelope Proteins / immunology*
-
Viral Vaccines / administration & dosage*
-
Viral Vaccines / immunology
-
Zika Virus / immunology*
-
Zika Virus Infection / immunology
-
Zika Virus Infection / prevention & control*
-
Zika Virus Infection / virology
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Recombinant Proteins
-
Viral Envelope Proteins
-
Viral Vaccines
Grants and funding
This study was supported in part by a National Key Program Project Grant from the Ministry of Science and Technology China (2016YFC1201000)(
http://www.most.gov.cn/), a National Science Foundation of China grant (31670941)(
http://www.nsfc.gov.cn/), and The Strategic Priority Research Program of the Chinese Academy of Sciences (XDPB030405)(
http://www.cas.cn/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.